We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
(+81%)
Cap. Flow
+$45.1M
Cap. Flow
% of AUM
6.18%
Top 10 Holdings %
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$40.8M |
| 2 |
United Therapeutics
UTHR
|
+$26.2M |
| 3 |
HSKA
Heska Corp
HSKA
|
+$20M |
| 4 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$18.2M |
| 5 |
AstraZeneca
AZN
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ChemoCentryx, Inc.
CCXI
|
+$29.3M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$27.8M |
| 3 |
Danaher
DHR
|
+$20.4M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$15.4M |
| 5 |
GSK
GSK
|
+$11.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.4% |
| 2 | Miscellaneous | 16.98% |
| 3 | Communication Services | 1.62% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$805B
| $105M | 14.38% |
340,000
+280,000
| +467% | +$82M |
2019 Q4
2 quarters
|
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $53.1M | 7.28% |
+954,738
| New | +$40.8M |
2020 Q2
0 quarters
|
|
3
TG Therapeutics
TGTX
$8.31B
| $48.7M | 6.68% |
2,501,272
+40,135
| +2% | +$646K |
2018 Q1
9 quarters
|
|
4
Amarin Corp
AMRN
$238M
| $33.1M | 4.54% |
239,305
+64,102
| +37% | +$8.82M |
2018 Q1
9 quarters
|
|
|
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $32.8M | 4.49% |
448,264
+341,879
| +321% | +$18.2M |
2020 Q1
1 quarter
|
|
6
Ascendis Pharma A/S
ASND
$14.8B
| $32.6M | 4.47% |
220,344
-55,150
| -20% | -$7.57M |
2017 Q4
10 quarters
|
|
|
7
AstraZeneca
AZN
$255B
| $29.7M | 4.08% |
281,076
+104,800
| +59% | +$10.8M |
2019 Q4
2 quarters
|
|
|
8
United Therapeutics
UTHR
$22.8B
| $28.2M | 3.86% |
+232,676
| New | +$26.2M |
2020 Q2
0 quarters
|
|
|
ZGNX
9
DELISTED
Zogenix, Inc.
ZGNX
| $27.2M | 3.73% |
1,007,083
-1,006,384
| -50% | -$27.8M |
2017 Q4
10 quarters
|
|
|
HSKA
10
DELISTED
Heska Corp
HSKA
| $26.1M | 3.58% |
280,256
+259,485
| +1,249% | +$20M |
2019 Q1
5 quarters
|
|
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $25M | 3.43% |
418,652
+4,571
| +1% | +$245K |
2018 Q4
6 quarters
|
|
12
BioCryst Pharmaceuticals
BCRX
$1.99B
| $23.1M | 3.17% |
4,847,792
-2,694,580
| -36% | -$10.8M |
2017 Q4
10 quarters
|
|
|
13
Danaher
DHR
$161B
| $19.1M | 2.62% |
121,663
-142,240
| -54% | -$20.4M |
2018 Q3
7 quarters
|
|
14
Fate Therapeutics
FATE
$218M
| $18.2M | 2.5% |
531,258
+225,773
| +74% | +$6.73M |
2018 Q4
6 quarters
|
|
15
The Ensign Group
ENSG
$10.3B
| $17.9M | 2.46% |
427,307
+70,279
| +20% | +$2.79M |
2017 Q4
10 quarters
|
|
|
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
| $15.7M | 2.15% |
+760,551
| New | +$10.3M |
2020 Q2
0 quarters
|
|
|
17
DELISTED
Apellis Pharmaceuticals
APLS
| $13.7M | 1.89% |
420,932
-478,542
| -53% | -$15.4M |
2018 Q2
8 quarters
|
|
18
DELISTED
MODEL N, INC.
MODN
| $11.8M | 1.62% |
340,764
-33,520
| -9% | -$977K |
2019 Q3
3 quarters
|
|
19
Sarepta Therapeutics
SRPT
$1.82B
| $11.5M | 1.58% |
+71,731
| New | +$9.76M |
2020 Q2
0 quarters
|
|
|
20
GSK
GSK
$99.4B
| $9.27M | 1.27% |
181,810
-226,647
| -55% | -$11.6M |
2018 Q1
9 quarters
|
|
21
Celldex Therapeutics
CLDX
$2.18B
| $9.27M | 1.27% |
+712,698
| New | +$3.16M |
2020 Q2
0 quarters
|
|
22
Aurinia Pharmaceuticals
AUPH
$2.2B
| $8.91M | 1.22% |
+548,325
| New | +$8.78M |
2020 Q2
0 quarters
|
|
23
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$45.7B
| $8.01M | 1.1% |
+80,000
| New | +$7.9M |
2020 Q2
0 quarters
|
|
|
24
CALL
Amarin Corp
AMRN
$238M
| $7.48M | 1.03% |
54,015
+2,835
| +6% | +$390K |
2019 Q3
3 quarters
|
|
25
Liquidia Corp
LQDA
$3.04B
| $7.24M | 0.99% |
859,724
+615,087
| +251% | +$4.67M |
2019 Q4
2 quarters
|
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.
- Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
- Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
- Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
- Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
- Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
- Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
- Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.
Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.